Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,371.84
(
-0.49%
)
US TECH 100
28,065.20
(
-1.03%
)
Dow Jones
49,553.41
(
0.06%
)
Brent Oil
107.80
(
0.31%
)
Bitcoin
76,367.01
(
-1.35%
)
News Focus
News Focus
Post# of 257581
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 42539

Tuesday, 02/27/2007 6:10:12 PM

Tuesday, February 27, 2007 6:10:12 PM

Post# of 257581
HGSI Albuferon addendum:

The non-inferiority threshold in the two phase-3 trials is 6% (12% if calculated as two-sided). The trials are powered at 90% to achieve non-inferiority vs Pegasys for at least one of the two Albuferon doses.

The power for showing superiority of at least one dose of Albuferon to Pegasys is closer to 80%.

Source: Today’s CC

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today